1–10 of 95 results for Proliferative Diabetic Retinopathy
Association Between DRSS Changes and Visual/ Anatomic Outcomes in Patients With Moderately Severe to Severe NPDR: Post Hoc Analysis of PANORAMA
Diana V Do, MD, FASRS
Annual Meeting Talks
2022
New Tool for Predicting the 3-Year Risk of Vision-Threatening Diabetic Retinopathy in Patients With Type 2 Diabetes Mellitus
Bobeck S Modjtahedi, MD
Intravitreal Methotrexate Reduces Reoperation Rate and Improves Vision After Vitrectomy for Retinal Detachment, Trauma, and Proliferative Diabetic Retinopathy
Alan J. Franklin, MD, PhD
Proliferative Diabetic Retinopathy
Aditya S Kelkar, MS, FRCS, FASRS,FRCOphth
Retina Image Bank: Images of the Week
2024
High risk Proliferative Diabetic Retinopathy treated with Pan Retinal Photocoagulation
Somnath Chakraborty, MD
Proliferative Diabetic Retinopathy with Macular Isquemia by OCT Angiography
JORGE SOBERANES
Impact of Intravitreal Anti-VEGF Therapy for Severe Non-Proliferative Diabetic Retinopathy (NPDR): Analyses Through a Monte-Carlo Simulation Model
Andrew A. Moshfeghi, MD, MBA, FASRS
On Demand Cases, Courses, and Papers
2021
Aflibercept Versus Vitrectomy With Panretinal Photocoagulation for Vitreous Hemorrhage From Proliferative Diabetic Retinopathy
Hani Salehi-Had, MD
Gabriel Costa Andrade, PhD
Loss to Follow-up in Patients With Proliferative Diabetic Retinopathy Treated With Anti-VEGF Therapy and/or PRP in the United States
Rahul N. Khurana, MD, FASRS